Related Experiment Video

Updated: Jun 8, 2026

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Progressive multifocal leukoencephalopathy and newer biological agents

Joseph R Berger1

  • 1Department of Neurology, University of Kentucky College of Medicine, Lexington, Kentucky 40536-0284, USA. jrbneuro@uky.edu

Drug Safety
|October 8, 2010
PubMed

Insights

Progressive multifocal leukoencephalopathy (PML), a rare brain disease caused by JC virus, is linked to immunosuppression. Certain monoclonal antibodies, like natalizumab, uniquely increase PML risk, prompting research into mitigation strategies.

Area of Science:

  • Neuroimmunology
  • Virology
  • Pharmacology

Background:

  • Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating brain disease caused by JC virus, typically occurring in immunocompromised individuals.
  • Acquired immunodeficiency syndrome (AIDS) has been the most common predisposing factor for PML over the past 30 years.
  • The emergence of PML with specific monoclonal antibody therapies has raised safety concerns and offered insights into disease pathogenesis.

Purpose of the Study:

  • To review the risk of PML associated with monoclonal antibodies and other pharmacological agents.
  • To propose a biologically plausible explanation for the increased PML risk.
  • To explore potential strategies for mitigating PML risk.

Main Methods:

  • Review of available data on PML risk with various therapeutic agents.
  • Analysis of the association between specific drug classes (e.g., monoclonal antibodies) and PML.
  • Investigation into the immunological mechanisms underlying PML development.

Main Results:

  • Certain monoclonal antibodies, including natalizumab and efalizumab, appear to uniquely predispose patients to PML.
  • PML occurrence with other agents like rituximab or mycophenolate mofetil is often associated with pre-existing risk factors for PML.
  • The pathogenesis of PML is being elucidated through the study of these drug-associated cases.

Conclusions:

  • Monoclonal antibodies and other immunosuppressive drugs necessitate careful risk-benefit assessment regarding PML.
  • Understanding the specific mechanisms of immune suppression is crucial for predicting and preventing PML.
  • Further research is needed to develop effective strategies for mitigating PML risk in patients undergoing these therapies.

More Related Videos

High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum10:19

High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum

Published on: November 23, 2013

Isolation of Brain-infiltrating Leukocytes06:44

Isolation of Brain-infiltrating Leukocytes

Published on: June 13, 2011

Related Concept Videos

Encephalitis l: Introduction01:19

Encephalitis l: Introduction

Encephalitis is inflammation of the brain parenchyma, most often due to infections or autoimmune processes. It presents with neuropsychiatric features such as fever, altered mental status, behavioral changes, cognitive dysfunction, seizures, focal deficits, and sometimes autonomic instability. In some cases, the meninges are also involved, resulting in meningoencephalitis.Infectious CausesInfectious encephalitis is most commonly viral but can also result from bacterial, fungal, or parasitic...
Encephalitis ll: Pathophysiology01:26

Encephalitis ll: Pathophysiology

Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Arboviral Encephalitis01:25

Arboviral Encephalitis

Arboviral encephalitis refers to brain inflammation caused by arthropod-borne viruses, particularly those transmitted through mosquito vectors. Among these, West Nile virus (WNV), a member of the Flaviviridae family, is a significant public health concern. WNV is an enveloped, positive-sense, single-stranded RNA virus. Human infection typically begins when an infected mosquito introduces the virus into the dermis during feeding. The primary transmission cycle involves birds as amplifying hosts...